Non-Hodgkin Lymphoma: Symptoms, Treatment, and Survival Rates

What is Non-Hodgkin Lymphoma?

Non-Hodgkin lymphoma (NHL) is a cancer that originates in the cells of the immune system. This system is a complex network of cells and tissues responsible for fighting infections and protecting the body against disease.

The lymphatic system is a key component of the immune system and comprises:

• Lymphatic vessels: A network of thin tubes branching throughout the body’s tissues, transporting lymph fluid.
• Lymph: A clear fluid that circulates within the lymphatic vessels. It contains white blood cells, primarily B and T lymphocytes, which defend against pathogens and abnormal cell growth.
• Lymph nodes: Small, round structures connected to the lymphatic vessels, functioning as biological filters. They are distributed throughout the body, with major clusters in the neck, armpits, chest, abdomen, and groin. Lymph nodes trap and eliminate bacteria and other harmful substances from the lymph, and store white blood cells.
• Other organs: Additional organs forming part of the lymphatic system include the tonsils, thymus, and spleen. Lymphatic tissue is also found in the stomach, skin, and small intestine.

Because lymphatic tissue is present throughout the body, lymphoma can develop virtually anywhere. It most commonly originates in a lymph node above the diaphragm, which is the thin muscle separating the chest from the abdomen. However, it can arise in any part of the lymphatic system.

Non-Hodgkin lymphoma begins with a genetic mutation in a lymphocyte (usually a B or T lymphocyte). The abnormal cell divides and replicates uncontrollably, producing increasing numbers of malignant cells that:

• Cannot protect the body against infections or other threats
• Do not die when they should (unlike healthy cells, which have a programmed lifespan)
• Accumulate in lymph nodes and other tissues, forming a mass known as a tumor

Survival and Prognosis

The first question most patients ask after a non-Hodgkin lymphoma diagnosis is: “What are my chances of survival?” The answer depends on many factors, including tumor subtype, stage, age, and general health. However, from a general perspective, United States cancer statistics show that the overall 5-year survival rate exceeds 72%. Thanks to advances in immunotherapy and cellular therapies, these figures continue to improve, even for the most aggressive forms.

More detailed survival data by subtype and stage:

Diffuse Large B-Cell Lymphoma (DLBCL)

Follicular Lymphoma

Key Prognostic Factors

The following factors significantly influence the prediction of disease course and outcome:

The International Prognostic Index (IPI), which incorporates age, LDH level, functional status, disease stage, and number of extranodal sites, is the most widely used tool for predicting outcomes in aggressive NHL subtypes.

---

Causes

Determining exactly why non-Hodgkin lymphoma develops in a specific individual is often difficult. In many cases, it is even impossible. Research has, however, identified a number of risk factors that increase the probability of developing the disease:

• Weakened immune system: Immunosuppression significantly raises NHL risk, whether it stems from an inherited immune deficiency, long-term use of immunosuppressive drugs (such as after organ transplantation), or an autoimmune disease.

• Viral and bacterial infections: While NHL is not contagious, certain infections predispose to lymphoma development:

  • HIV (AIDS): Significantly increases the risk of several NHL subtypes.
  • Epstein-Barr virus (EBV) (the cause of infectious mononucleosis): Associated with increased NHL risk; linked to Burkitt lymphoma in Africa.
  • Helicobacter pylori: The bacterium responsible for gastric ulcers, which can promote the development of gastric mucosa-associated lymphoid tissue (MALT) lymphoma.
  • HTLV-1 (Human T-lymphotropic virus type 1): Increases risk of T-cell lymphoma and leukemia.
  • Hepatitis C virus: Research suggests an elevated NHL risk in HCV-infected individuals; the mechanisms are still under investigation.

• Age: While NHL can occur at any age, risk generally increases with advancing years. The majority of NHL patients are over 60 years old.

• Other potential risk factors under investigation: Researchers are exploring associations with obesity, occupational exposure to pesticides and certain chemicals, and autoimmune diseases such as rheumatoid arthritis and Sjögren’s syndrome.

Important: Having one or more risk factors does not mean a person will necessarily develop NHL. Statistically, the majority of individuals with risk factors never develop lymphoma.

Classification

The term lymphoma encompasses a broad group of cancers originating in lymphocytes (a subtype of white blood cells). The two main categories are:

• Hodgkin lymphoma
• Non-Hodgkin lymphoma (NHL)

The key distinction lies in the type of lymphocyte involved, as well as specific microscopic features. In particular, Reed-Sternberg cells, which are large and distinctive cancer cells, are characteristic of Hodgkin lymphoma but are absent in non-Hodgkin lymphoma.

Non-Hodgkin lymphomas account for approximately 90% of all lymphoma cases and encompass a large and heterogeneous group of subtypes. The primary classification divides them by cell of origin:

• B-cell lymphomas: approximately 90% of NHL cases
• T-cell lymphomas: approximately 10% of NHL cases

Each category includes further subtypes based on:

• Aggressiveness (clinical behavior):
  • Indolent (slow-growing): gradual evolution, tendency toward chronicity and relapse, but often not immediately life-threatening
  • Aggressive: rapid onset with more severe symptoms, but paradoxically often more curable with intensive treatment
• Microscopic appearance (histology)
• Extent of disease spread

The most common NHL subtype overall is diffuse large B-cell lymphoma (DLBCL). This aggressive form is serious but responds well to modern combination therapy.

Precise subtype classification is essential because it directly determines the optimal treatment strategy for each patient.

---

Symptoms

Non-Hodgkin lymphoma can produce a variety of symptoms. Some of these are highly characteristic, while others are non-specific and may result from many other, more common conditions:

• Painless swelling of lymph nodes in the neck, armpits, or groin is often the first symptom to appear
• Unexplained weight loss: a significant and unintentional loss of body weight
• Persistent fever, which does not resolve or has no obvious infectious cause
• Drenching night sweats (soaking the bedclothes) can be alarming, though this symptom has many other possible causes
• Cough, breathing difficulties, or chest pain may occur when mediastinal (chest) lymph nodes are involved
• Persistent weakness and fatigue that does not improve with rest
• Abdominal pain, bloating, or a feeling of abdominal fullness from enlarged lymph nodes or organs within the abdomen

The so-called “B symptoms” (fever, drenching night sweats, and unexplained weight loss of more than 10% of body weight within 6 months) carry important prognostic significance and should always be specifically reported to the physician.

The first symptom is often a swollen lymph node, but in the vast majority of cases, lymph node enlargement is caused by infection or other benign conditions rather than cancer. However, if symptoms persist for more than two weeks without a clear explanation, medical evaluation is strongly recommended.

---

Diagnosis

The diagnostic pathway for non-Hodgkin lymphoma is highly precise and aims not only to confirm the presence of cancer but also to define its exact molecular subtype, a critical step for personalizing therapy.

Medical History and Physical Examination

Suspicion often arises during a routine medical visit or when a patient notices an enlarged lymph node. The physician will:

• Palpate lymph nodes in the neck, axillae, and groin, assessing consistency, mobility, and tenderness
• Examine the abdomen for splenomegaly or hepatomegaly (enlarged spleen or liver)
• Take a full medical history, focusing on symptoms, duration, associated complaints, and risk factor exposure

Lymph Node Biopsy: The Gold Standard

Biopsy is the only definitive method for diagnosing lymphoma. Current protocols recommend, whenever possible, excisional biopsy, which is the complete surgical removal of an entire lymph node. Fine needle aspiration (FNA) alone is considered insufficient for a complete lymphoma diagnosis, as it does not preserve the tissue architecture necessary to distinguish between subtypes.

The tissue sample undergoes multiple analyses:

• Immunohistochemistry (IHC): Identifies specific proteins on the cell surface (e.g., CD20 for B lymphocytes, CD3 for T lymphocytes), enabling precise subtype classification
• Flow cytometry: Analyzes thousands of individual cells simultaneously to confirm their malignant nature and lineage
• Molecular testing (Next-Generation Sequencing, NGS): Identifies specific genetic mutations that influence prognosis and guide the selection of targeted therapies (e.g., MYC rearrangement in DLBCL, BCL-2 translocation in follicular lymphoma)

Blood Tests and Biomarkers

Laboratory investigations provide critical information about the patient’s general health and tumor behavior:

• Complete blood count (CBC): Identifies anemia, leukopenia, or thrombocytopenia from bone marrow involvement
• Lactate dehydrogenase (LDH): Elevated levels indicate high tumor cell turnover, a marker of aggressive disease
• Beta-2 microglobulin: Elevated in many hematological malignancies; useful as a prognostic marker
• Viral serology (HIV, Hepatitis B, and Hepatitis C): Essential before planning immunotherapy or chemotherapy to prevent reactivation of latent infections

Imaging and Staging

Advanced imaging technology is used to determine the extent and distribution of disease:

• PET/CT scan: The current standard of care. Combines the anatomical precision of CT with PET’s ability to identify metabolically active (living and dividing) tumor cells. PET/CT is used both for initial staging and for assessing treatment response.
• MRI (Magnetic Resonance Imaging): Used primarily when central nervous system (CNS) or spinal cord involvement is suspected.
• Bone marrow biopsy: Previously performed routinely, it is now often omitted when PET/CT clearly demonstrates bone marrow involvement. Still recommended in certain subtypes.

Staging follows the Lugano classification (based on the older Ann Arbor system), from Stage I (single lymph node region) to Stage IV (widespread dissemination to multiple organs).

---

Treatment

The treatment of non-Hodgkin lymphoma has undergone a genuine revolution with the introduction of biological drugs and cellular therapies. The primary goal is complete remission (the disappearance of all detectable disease) while preserving the patient’s quality of life as much as possible.

Indolent Lymphomas and Watchful Waiting

For slow-growing forms (such as early-stage follicular lymphoma) that are asymptomatic and not causing organ dysfunction, the preferred initial strategy may be active surveillance (watchful waiting). Studies confirm that initiating aggressive therapy in the absence of symptoms does not always improve survival and may expose the patient to unnecessary side effects. Treatment is initiated only when signs of disease progression appear (known as “GELF criteria” or similar threshold indicators).

Chemotherapy and Immunotherapy: The Winning Combination

For the majority of patients requiring treatment, the cornerstone of care is the combination of chemotherapy and monoclonal antibodies:

• R-CHOP: The international standard protocol for diffuse large B-cell lymphoma. Combines Rituximab (an anti-CD20 monoclonal antibody) with a four-drug chemotherapy regimen (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone). It achieves complete remission in approximately 60–70% of patients with DLBCL.
• Targeted immunotherapy: Monoclonal antibodies “label” tumor cells so that the patient’s own immune system can recognize and destroy them, acting far more selectively than chemotherapy alone and with a distinct toxicity profile.

Other immunochemotherapy regimens (BR for follicular lymphoma, CHOP variants for T-cell lymphomas) are selected based on histological subtype and patient characteristics.

Innovative Therapies: Bispecific and Conjugated Antibodies

For relapsed, refractory, or more complex cases, modern oncology offers:

• Bispecific antibodies (e.g., mosunetuzumab, glofitamab, epcoritamab): “Two-armed” drugs that simultaneously engage the lymphoma cell (via one arm) and a T lymphocyte (via the other), physically forcing immune-mediated destruction of the tumor. These are administered as outpatient infusions or subcutaneous injections, representing a major step forward in accessibility.
• Antibody-drug conjugates (ADCs) (e.g., polatuzumab vedotin in combination with BR): Monoclonal antibodies chemically linked to a potent cytotoxic payload, delivering chemotherapy precisely inside the tumor cell while sparing healthy tissues. Dramatically improves the therapeutic index compared to systemic chemotherapy.

CAR-T: The Frontier of Cellular Therapies

For patients who do not respond to or relapse after conventional treatments, CAR-T cell therapy has emerged as a potentially curative option. The process involves:

1. Collecting the patient’s own T lymphocytes via leukapheresis
2. Genetically engineering them in the laboratory to express a Chimeric Antigen Receptor (CAR) specifically targeting a protein on the lymphoma cell surface (typically CD19)
3. Re-infusing the engineered cells back into the patient, where they proliferate and actively seek and destroy tumor cells

CAR-T therapy (products such as axicabtagene ciloleucel and tisagenlecleucel) has achieved remarkable and durable remissions in patients with relapsed/refractory DLBCL. It is a complex procedure performed only in highly specialized hematology centers, given the potential for serious side effects (cytokine release syndrome, neurotoxicity) requiring intensive monitoring.

Radiation Therapy and Stem Cell Transplantation

• Radiation therapy: Used as consolidation therapy after chemotherapy on residual tumor masses (particularly in localized disease), as part of combined modality treatment in certain subtypes, or for palliative symptom control.
• Stem cell transplantation: Autologous transplantation (using the patient’s own previously collected stem cells) remains a key strategy for consolidating remission after first relapse, enabling delivery of very high doses of chemotherapy followed by stem cell “rescue”. Allogeneic transplantation (from a donor) is considered in selected high-risk cases.

Lifestyle and Supportive Care During Treatment

Modern lymphoma care recognizes and addresses the full impact of the disease on daily life:

• Nutrition: A balanced diet rich in high-quality proteins and low in refined sugars is essential to support the body during intensive treatment. An oncology dietitian can provide personalized guidance for managing treatment-related symptoms such as nausea, taste changes, and loss of appetite.
• Physical activity: Gentle walking, yoga, or swimming (as approved by the treating physician) have been shown to significantly reduce cancer-related fatigue, one of the most burdensome side effects of lymphoma treatment, and improve mood and psychological resilience.
• Management of side effects: Modern anti-emetic drugs, granulocyte colony-stimulating factors (G-CSF) to prevent dangerous decreases in white blood cell count, and supportive transfusions make treatment regimens far more tolerable than in the past.
• Psychological support: Anxiety and depression are common in NHL patients. Psychological support, such as individual counseling, peer support groups, or mindfulness-based programs, is now considered an integral part of comprehensive cancer care.

---

Diet and Physical Activity

Taking care of one’s general wellbeing through healthy eating and regular physical activity is important for all NHL patients, both during and after treatment.

To maintain a healthy body weight and preserve muscle mass, it is important to:

• Consume an adequate number of calories for your activity level and treatment phase
• Ensure sufficient protein intake (lean meats, fish, eggs, legumes, dairy) to protect muscle strength and support immune recovery
• Stay well hydrated, especially during chemotherapy

During treatment, reduced appetite, nausea, and taste alterations are common. Side effects such as mouth sores, vomiting, or profound fatigue may make eating well challenging. Your physician, dietitian, or the multidisciplinary care team can suggest practical strategies to manage these issues.

Many patients report significant benefits from maintaining physical activity during treatment:

• Walking, yoga, swimming, or other low-impact activities help preserve muscle strength and combat fatigue
• Exercise has been shown to reduce nausea, pain, and stress, and to improve treatment tolerance and overall wellbeing
• Even modest levels of activity are beneficial. Start slowly, listen to your body, and always check with your doctor before beginning any exercise program
• If any physical activity causes pain, increased swelling, or other concerning symptoms, inform your medical team immediately

---

Frequently Asked Questions

How long can you live with non-Hodgkin lymphoma?

The overall 5-year survival rate is greater than 72%, but this figure varies significantly depending on:

• The specific NHL subtype (e.g., follicular lymphoma has a 5-year survival exceeding 88%, while some aggressive subtypes are lower)
• The stage at diagnosis (localized vs. widespread disease)
• The patient’s age and general health status
• Response to treatment

Thanks to CAR-T therapy, bispecific antibodies, and other advances, survival rates for many NHL subtypes, including historically aggressive ones, continue to improve.

How does someone die from non-Hodgkin lymphoma?

The most common causes of death from NHL include:

• Serious infections: The disease and its treatments impair immune function, making patients vulnerable to bacterial, viral, and fungal infections that can become life-threatening
• Bleeding complications: Bone marrow infiltration can reduce platelet production, increasing hemorrhagic risk
• Organ failure: Caused by extensive tumor infiltration of vital organs (liver, kidneys, lungs)
• Treatment-related complications: In some cases, toxicity from chemotherapy or transplant complications may be contributing factors

Palliative and supportive care plays a crucial role in managing these complications and maintaining quality of life, particularly in advanced or refractory disease.

What is the difference between Hodgkin and non-Hodgkin lymphoma?

The key distinctions are:

Is non-Hodgkin lymphoma curable?

Many forms of NHL are potentially curable, particularly aggressive subtypes such as DLBCL, in which 60–70% of patients achieve long-term remission with R-CHOP. Indolent forms (such as follicular lymphoma) are often not curable with current therapies but can be managed very effectively as chronic conditions for many years, often with excellent quality of life. CAR-T therapy has produced durable remissions in some relapsed/refractory patients who previously had very limited options.

---

Sources and Bibliography

• National Cancer Institute (NCI) – Lymphoma
• Castillo JJ, et al. Risk Factors of Non-Hodgkin Lymphoma. Hematology/Oncology Clinics of North America. 2011.
• Tilly H, et al. Non-Hodgkin Lymphoma: Diagnosis and Treatment. Mayo Clinic Proceedings. 2015;90(8):1162–1183.
• SEER Cancer Statistics – Non-Hodgkin Lymphoma. National Cancer Institute.
• American Cancer Society – Factors That Affect Prognosis for NHL.
• Sehn LH, Salles G. Diffuse Large B-Cell Lymphoma. New England Journal of Medicine. 2021;384(9):842–858.
• Neelapu SS, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. New England Journal of Medicine. 2017;377(26):2531–2544.
• Luminari S, et al. Follicular Lymphoma: Treatment and Prognosis. Seminars in Hematology. 2020.